

# Updated guidelines issued for ER, PgR testing in breast cancer

January 27 2020

---



(HealthDay)—In an American Society of Clinical Oncology/College of

American Pathologists updated guideline, published online Jan. 13 in the *Archives of Pathology & Laboratory Medicine* and the *Journal of Clinical Oncology*, recommendations are presented for estrogen and progesterone receptor (ER/PgR) testing in breast cancer.

Kimberly H. Allison, M.D., from the Stanford University School of Medicine in California, and colleagues convened a multidisciplinary international [expert panel](#) to update the clinical practice guideline recommendations for ER and PgR testing in [breast cancer](#).

The expert panel continues to recommend validated immunohistochemistry for ER testing of invasive breast cancers as the standard for predicting benefit from endocrine therapy. Samples with 1 to 100 percent of tumor nuclei positive should be considered ER-positive. However, limited data are available on the benefit of endocrine therapy for cancers with 1 to 10 percent of cells staining ER-positive, now described in a new reporting category called ER-low positive. A sample with

Citation: Updated guidelines issued for ER, PgR testing in breast cancer (2020, January 27)  
retrieved 2 May 2024 from

<https://medicalxpress.com/news/2020-01-guidelines-issued-er-pgr-breast.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--